22Dec
Cadent Therapeutics Acquired by Novartis for Up to $770 Million
Cadent Therapeutics, a Cambridge, Massachusetts-based, privately held clinical stage biopharmaceutical company focused on the development of therapies for the treatment of cognitive, mood, and movement disorders, announced on December 17, 2020, that Novartis will acquire all of the outstanding capital stock of Cadent Therapeutics....
By:
Rothwell, Figg, Ernst & Manbeck, P.C.
Related
After being on the verge of enactment last spring but failing to pass, the SECURE Act will become la...
Read More >
On Monday, August 17, 2020, Baker Donelson's Clinton Sanko sat down with Wendell Jisa, CEO of Reveal...
Read More >
The FTI Journal continues its look at opportunities for private equity in distressed M&A given the p...
Read More >
Keeping an eye on changes and trends in employment law is an excellent way for businesses to mitigat...
Read More >
The New Jersey test for independent contractor status under the unemployment laws is already very to...
Read More >
The last decade has brought with it a significant increase in the number of claims stemming from all...
Read More >